预约演示

Clover collaborates with Kyuan Trade to launch AdimFlu-S (QIS) in China

2023-05-25

并购上市批准疫苗

Clover Biopharmaceuticals will benefit from the extensive sales and distribution network of Kyuan Trade. Credit: Clover Biopharmaceuticals.

Clover Biopharmaceuticals has established a commercial collaboration with Keyuan Xinhai (Beijing) Medical ProductClover Biopharmaceuticalsor the launch of its quadrivalent seasonal influenza vaccine, AdimFlu-S (QIS), in China.

Clover Biopharmaceuticalsl Products Administration approved AdimFlu-S (QIS) in January 2022 for individuals aged three years and above.

Recommended ReportsAdimFlu-S

ReportsChina Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Valu... GlobalData

ReportsGlobal Mergers and Acquisitions (M&A) Deals in Pharma 2021 - Thematic Research GlobalData

View all

The vaccine contains haemagglutinin from four influenza virus strains, two A and two B.

This increases the vaccine’s chance of high effectivenPharmaainst seasonal influenza compared to trivalent options.

Clover Biopharmaceuticals will use Kyuan Trade’s extensive sales and distribution network to complement its in-house capabilities and increase access to its AdimFlu-S (QIS) across the country.

Clover Biopharmaceuticals CEO and executive diinfluenzashua Liang stated: “We are thrilled to partner with Kyuan Trade, which has a large and talented commercial team, a broad distribution network that extends across 31 provinces, municipalities and autonomous regions, and an excellent modern logistics network.

“With the seasonal influenza market in China poised for continued seasonal influenzaership is expected to help accelerate our commercial success and near-term revenue potential.”

Clover Biopharmaceuticalse seasonal influenza vaccine has been growing by 30% per year.

Clover Biopharmaceuticals expects to launch the influenza vaccine in the second half of 2023.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构